Overweight as a prognostic factor for triple-negative breast cancers in Chinese women

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Hao, Shuang ^a,b   Liu, Yin ^a,b   Yu, Ke Da ^a,b   Chen, Sheng ^a,b   Yang, Wen Tao ^a,b   Shao, Zhi Min ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CANCER SIZE; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; CHINESE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MENOPAUSE; OBESITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTMENOPAUSE; PREMENOPAUSE; TRIPLE NEGATIVE BREAST CANCER; VERY ELDERLY; ASIAN CONTINENTAL ANCESTRY GROUP; BODY WEIGHT; CHINA; COMPLICATION; FACTUAL DATABASE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; BODY MASS INDEX; BODY WEIGHT; CHINA; DATABASES, FACTUAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MENOPAUSE; MIDDLE AGED; OVERWEIGHT; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS; YOUNG ADULT;

EID: 84939174187     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0129741     Document Type: Article

References (30)

1. Ades F, Zardavas D, Bozovic-Spasojevic I, Pugliano L, Fumagalli D, de Azambuja E, et al. Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2014. doi: 10.1200/JCO.2013.54.1870 PMID: 25049332.
2. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. Jama. 2006; 295(21):2492-502. doi: 10.1001/jama.295.21.2492 PMID: 16757721.
3. Dawood S, Broglio K, Gonzalez-Angulo AM, Kau SW, Islam R, Hortobagyi GN, et al. Prognostic value of body mass index in locally advanced breast cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2008; 14(6):1718-25. doi: 10.1158/1078-0432.CCR-07-1479 PMID: 18347172.
4. Kroenke CH, Chen WY, Rosner B, Holmes MD. Weight, weight gain, and survival after breast cancer diagnosis. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2005; 23(7):1370-8. doi: 10.1200/JCO.2005.01.079 PMID: 15684320.
5. Caan BJ, Kwan ML, Hartzell G, Castillo A, Slattery ML, Sternfeld B, et al. Pre-diagnosis body mass index, post-diagnosis weight change, and prognosis among women with early stage breast cancer. Cancer causes & control: CCC. 2008; 19(10):1319-28. doi: 10.1007/s10552-008-9203-0 PMID: 18752034; PubMed Central PMCID: PMC2925505.
6. Ewertz M, Jensen MB, Gunnarsdottir KA, Hojris I, Jakobsen EH, Nielsen D, et al. Effect of obesity on prognosis after early-stage breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011; 29(1):25-31. doi: 10.1200/JCO.2010.29.7614 PMID: 21115856.
7. Mowad R, Chu QD, Li BD, Burton GV, Ampil FL, Kim RH. Does obesity have an effect on outcomes in triple-negative breast cancer? The Journal of surgical research. 2013; 184(1):253-9. doi: 10.1016/j.jss.2013.05.037 PMID: 23768767.
8. Zhou BF, Cooperative Meta-Analysis Group of the Working Group on Obesity in C. Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults - study on optimal cut-off points of body mass index and waist circumference in Chinese adults. Biomedical and environmental sciences: BES. 2002; 15(1):83-96. PMID: 12046553.
9. Shimada A, Kimura S, Abe K, Nagasaki K, Adachi I, Yamaguchi K, et al. Immunocytochemical staining of estrogen receptor in paraffin sections of human breast cancer by use of monoclonal antibody: comparison with that in frozen sections. Proceedings of the National Academy of Sciences of the United States of America. 1985; 82(14):4803-7. PMID: 3860824; PubMed Central PMCID: PMC390993.
10. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010; 28(16):2784-95. doi: 10.1200/JCO.2009.25.6529 PMID: 20404251; PubMed Central PMCID: PMC2881855.
11. Rody A, Diallo R, Poremba C, Speich R, Wuelfing P, Kissler S, et al. Estrogen receptor alpha and beta, progesterone receptor, pS2 and HER-2/neu expression delineate different subgroups in ductal carcinoma in situ of the breast. Oncology reports. 2004; 12(4):695-9. PMID: 15375487.
12. Gouvea AP, Milanezi F, Olson SJ, Leitao D, Schmitt FC, Gobbi H. Selecting antibodies to detect HER2 overexpression by immunohistochemistry in invasive mammary carcinomas. Applied immunohistochemistry & molecular morphology: AIMM / official publication of the Society for Applied Immunohistochemistry. 2006; 14(1):103-8. doi: 10.1097/01.pai.0000155794.64525.11 PMID: 16540740.
13. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 1999; 17(7):1983-7. PMID: 10561248.
14. Datema FR, Moya A, Krause P, Back T, Willmes L, Langeveld T, et al. Novel head and neck cancer survival analysis approach: random survival forests versus Cox proportional hazards regression. Head &neck. 2012; 34(1):50-8. doi: 10.1002/hed.21698 PMID: 21322080.
15. Ademuyiwa FO, Groman A, O'Connor T, Ambrosone C, Watroba N, Edge SB. Impact of body mass index on clinical outcomes in triple-negative breast cancer. Cancer. 2011; 117(18):4132-40. doi: 10.1002/cncr.26019 PMID: 21387276.
16. Majed B, Moreau T, Senouci K, Salmon RJ, Fourquet A, Asselain B. Is obesity an independent prognosis factor in woman breast cancer? Breast cancer research and treatment. 2008; 111(2):329-42. doi: 10.1007/s10549-007-9785-3 PMID: 17939036.
17. Berclaz G, Li S, Price KN, Coates AS, Castiglione-Gertsch M, Rudenstam CM, et al. Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2004; 15(6):875-84. PMID: 15151943.
18. de Azambuja E, McCaskill-Stevens W, Francis P, Quinaux E, Crown JP, Vicente M, et al. The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial. Breast cancer research and treatment. 2010; 119(1):145-53. doi: 10.1007/s10549-009-0512-0 PMID: 19731015.
19. Ladoire S, Dalban C, Roche H, Spielmann M, Fumoleau P, Levy C, et al. Effect of obesity on disease-free and overall survival in node-positive breast cancer patients in a large French population: a pooled analysis of two randomised trials. European journal of cancer. 2014; 50(3):506-16. doi: 10.1016/j.ejca.2013.11.013 PMID: 24315625.
20. Chen X, Lu W, Zheng W, Gu K, Chen Z, Zheng Y, et al. Obesity and weight change in relation to breast cancer survival. Breast cancer research and treatment. 2010; 122(3):823-33. doi: 10.1007/s10549-009-0708-3 PMID: 20058068; PubMed Central PMCID: PMC3777404.
21. Dawood S, Lei X, Litton JK, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM. Impact of body mass index on survival outcome among women with early stage triple-negative breast cancer. Clinical breast cancer. 2012; 12(5):364-72. doi: 10.1016/j.clbc.2012.07.013 PMID: 23040004.
22. Turkoz FP, Solak M, Petekkaya I, Keskin O, Kertmen N, Sarici F, et al. The prognostic impact of obesity on molecular subtypes of breast cancer in premenopausal women. Journal of BUON: official journal of the Balkan Union of Oncology. 2013; 18(2):335-41. PMID: 23818343.
23. Pierobon M, Frankenfeld CL. Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis. Breast cancer research and treatment. 2013; 137(1):307-14. doi: 10.1007/s10549-012-2339-3 PMID: 23179600.
24. Tait S, Pacheco JM, Gao F, Bumb C, Ellis MJ, Ma CX. Body mass index, diabetes, and triple-negative breast cancer prognosis. Breast cancer research and treatment. 2014; 146(1):189-97. doi: 10.1007/s10549-014-3002-y PMID: 24869799.
25. Fontanella C, Lederer B, Gade S, Vanoppen M, Blohmer JU, Costa SD, et al. Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials. Breast cancer research and treatment. 2015; 150(1):127-39. doi: 10.1007/s10549-015-3287-5 PMID: 25677740.
26. Pajares B, Pollan M, Martin M, Mackey JR, Lluch A, Gavila J, et al. Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis. Breast cancer research: BCR. 2013; 15(6):R105. doi: 10.1186/bcr3572 PMID: 24192331; PubMed Central PMCID: PMC3978725.
27. Nelson ER, Wardell SE, Jasper JS, Park S, Suchindran S, Howe MK, et al. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science. 2013; 342(6162):1094-8. doi: 10.1126/science.1241908 PMID: 24288332; PubMed Central PMCID: PMC3899689.
28. Zheng Q, Banaszak L, Fracci S, Basali D, Dunlap SM, Hursting SD, et al. Leptin receptor maintains cancer stem-like properties in triple negative breast cancer cells. Endocrine-related cancer. 2013; 20 (6):797-808. doi: 10.1530/ERC-13-0329 PMID: 24025407; PubMed Central PMCID: PMC3843956.
29. Howe LR, Subbaramaiah K, Hudis CA, Dannenberg AJ. Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2013; 19(22):6074-83. doi: 10.1158/1078-0432.CCR-12-2603 PMID: 23958744; PubMed Central PMCID: PMC3891839.
30. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52. doi: 10.1038/35021093 PMID: 10963602.